[go: up one dir, main page]

MX363896B - Combinación de un antagonista de cxcr4y y citarabina para el uso en el tratamiento de leucemia mieloide. - Google Patents

Combinación de un antagonista de cxcr4y y citarabina para el uso en el tratamiento de leucemia mieloide.

Info

Publication number
MX363896B
MX363896B MX2015013525A MX2015013525A MX363896B MX 363896 B MX363896 B MX 363896B MX 2015013525 A MX2015013525 A MX 2015013525A MX 2015013525 A MX2015013525 A MX 2015013525A MX 363896 B MX363896 B MX 363896B
Authority
MX
Mexico
Prior art keywords
myeloid leukemia
methods
treating myeloid
treating
effective amount
Prior art date
Application number
MX2015013525A
Other languages
English (en)
Other versions
MX2015013525A (es
Inventor
Peled Amnon
Pereg Yaron
Original Assignee
Biokine Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biokine Therapeutics Ltd filed Critical Biokine Therapeutics Ltd
Publication of MX2015013525A publication Critical patent/MX2015013525A/es
Publication of MX363896B publication Critical patent/MX363896B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona un método para tratar una leucemia mieloide. El método incluye la etapa de administrar a un sujeto en necesidad del mismo una cantidad terapéuticamente efectiva de un péptido antagonístico de CXCR4 y una cantidad terapéuticamente efectiva de un agente quimioterapéutico.
MX2015013525A 2013-03-24 2014-03-19 Combinación de un antagonista de cxcr4y y citarabina para el uso en el tratamiento de leucemia mieloide. MX363896B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361804677P 2013-03-24 2013-03-24
PCT/IL2014/050303 WO2014155376A1 (en) 2013-03-24 2014-03-19 Methods of treating myeloid leukemia

Publications (2)

Publication Number Publication Date
MX2015013525A MX2015013525A (es) 2016-07-18
MX363896B true MX363896B (es) 2019-04-05

Family

ID=50483415

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013525A MX363896B (es) 2013-03-24 2014-03-19 Combinación de un antagonista de cxcr4y y citarabina para el uso en el tratamiento de leucemia mieloide.

Country Status (13)

Country Link
US (3) US20160082071A1 (es)
EP (1) EP2978439B1 (es)
JP (1) JP6294459B2 (es)
KR (1) KR20150135432A (es)
CN (1) CN105163749B (es)
AU (2) AU2014240733B2 (es)
BR (1) BR112015024558A2 (es)
CA (1) CA2906314A1 (es)
ES (1) ES2643321T3 (es)
HK (1) HK1215790A1 (es)
IL (1) IL240924B (es)
MX (1) MX363896B (es)
WO (1) WO2014155376A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2442822B1 (en) 2009-06-14 2014-03-05 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
WO2015063768A1 (en) * 2013-10-31 2015-05-07 Biokine Therapeutics Ltd. Methods of treating acute myeloid leukemia with a flt3 mutation
EP3943098A3 (en) 2015-07-16 2022-05-11 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
BR112018016924A2 (pt) * 2016-02-23 2019-01-02 Biokine Therapeutics Ltd método de seleção de regime de tratamento para indivíduo que tem leucemia mieloide aguda (lma), método de maximização de resposta ao tratamento de leucemia mieloide aguda (lma), método de tratamento de lma, antagonista de cxcr4 e agente quimioterápico no tratamento de lma
TWI734027B (zh) * 2017-09-18 2021-07-21 泰宗生物科技股份有限公司 用於治療癌症之組合物
CN109517039B (zh) * 2017-09-20 2021-03-19 尚华医药科技(江西)有限公司 一种肽类化合物、其应用及含其的组合物
US20210338767A1 (en) 2018-09-25 2021-11-04 Biolinerx Ltd. Methods of selecting treatment for cxcr4-associated cancer
WO2020092259A1 (en) * 2018-10-29 2020-05-07 Molecular Stethoscope, Inc. Characterization of bone marrow using cell-free messenger-rna
CN110935008B (zh) * 2019-12-10 2023-09-26 昆明医科大学第一附属医院 一种关节腔注射治疗骨关节炎的tn14003温敏型凝胶及其制备方法
JP7441049B2 (ja) 2020-01-15 2024-02-29 カヤバ株式会社 ギヤの製造方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US39282A (en) * 1863-07-21 Improvement in ch aim-shot
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
JPS552602A (en) * 1978-06-20 1980-01-10 Yamasa Shoyu Co Ltd 1-beta-d-arabinofranosylcytosine-5'-phosphoric acid oleyl ester
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
WO2000009152A1 (en) 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
CA2421183C (en) 2000-09-05 2015-06-16 Seikagaku Corporation Novel polypeptide and anti-hiv agent containing the same
US7423007B2 (en) * 2002-08-27 2008-09-09 Biokine Therapeutics Ltd. Cxcr4 antagonist and use thereof
JP4781621B2 (ja) * 2002-08-27 2011-09-28 バイオカイン セラピューティックス リミテッド Ｃｘｃｒ４拮抗薬およびその用途
DE10240064A1 (de) 2002-08-30 2004-03-11 Universitätsklinikum Freiburg CXCR4-Rezeptor-Antagonisten
WO2004087068A2 (en) 2003-03-27 2004-10-14 Emory University Cxcr4 antagonists and methods of their use
CA2619828A1 (en) 2005-08-19 2007-02-22 Genzyme Corporation Methods to enhance chemotherapy

Also Published As

Publication number Publication date
JP6294459B2 (ja) 2018-03-14
US20180311308A1 (en) 2018-11-01
AU2014240733B2 (en) 2018-11-22
MX2015013525A (es) 2016-07-18
EP2978439A1 (en) 2016-02-03
CA2906314A1 (en) 2014-10-02
IL240924B (en) 2018-01-31
CN105163749B (zh) 2018-03-27
US20160082071A1 (en) 2016-03-24
IL240924A0 (en) 2015-10-29
EP2978439B1 (en) 2017-08-16
JP2016516080A (ja) 2016-06-02
CN105163749A (zh) 2015-12-16
HK1215790A1 (zh) 2016-09-15
AU2019200329A1 (en) 2019-02-07
ES2643321T3 (es) 2017-11-22
US20180344801A1 (en) 2018-12-06
BR112015024558A2 (pt) 2017-07-18
WO2014155376A1 (en) 2014-10-02
AU2014240733A1 (en) 2015-10-22
KR20150135432A (ko) 2015-12-02

Similar Documents

Publication Publication Date Title
MX363896B (es) Combinación de un antagonista de cxcr4y y citarabina para el uso en el tratamiento de leucemia mieloide.
PH12019501197A1 (en) Therapeutically active compounds and their methods of use
PH12016500164B1 (en) Therapeutically active compounds and their methods of use
PH12014501561A1 (en) Therapeutically active compounds and their methods of use
PH12015502075A1 (en) Treatment of cataplexy
MX2015014500A (es) Terapia de combinacion de anticuerpos contra csf-1r y agonista de tlr9.
HK1221178A1 (zh) 卡博替尼劑型及其在癌症治療中的使用
MX370573B (es) Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
WO2015003355A3 (en) Therapeutically active compounds and their methods of use
MX2015012106A (es) Combinacion de un inhibidor de egfr t790m y un inhibidor de egfr para el tratamiento del cancer pulmonar de celulas no pequeñas.
MX2017015896A (es) Agente anticancerigeno.
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
IL227374A0 (en) Aids for providing acupuncture treatment and other healing procedures
TW201613592A (en) Glucose metabolism ameliorating agent
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
MX2015011386A (es) Metodo para tratar cancer pancreatico.
MX2016002307A (es) Tratamiento para el cancer.
MX2015012344A (es) 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrameti ltetrahidro-2h-piran-4-il)piridin-3-il)-1h-imidazol-2-carboxamida para el tratamiento de linfona de hodgkin.
GEP20196947B (en) Bremelanotide therapy for female sexual dysfunction
MX2015014063A (es) Composicion anti tumoral que comprende un inhibidor selectivo pi3kbeta y un inhibidor selectivo pi3kalfa.
UA88266U (ru) Способ комплексной профилактики и лечения поражений слизистой оболочки полости рта на фоне химиотерапии
CA149964S (en) Scarf
UA86152U (ru) Способ лечения больных хроническим гепатитом с, которые имеют противопоказания к интерферонотерапии, и/или нон-респондеров
NZ745950A (en) Methods and compositions for treating multiple sclerosis and related disorders
UA88039U (uk) Спосіб профілактики ускладнень уреомікоплазмової інфекції в перинатальному та постнатальному періоді

Legal Events

Date Code Title Description
FG Grant or registration